As of the latest SEC filings, Adaptimmune Therapeutics PLC (ADAPY) is held by 1 institutional funds. The largest fund shareholder is Guggenheim Active Allocation Fund (GUG), holding an estimated $5.46 in market value, representing a significant portion of its portfolio.